Northland Capmk cut shares of XOS (NASDAQ:XOS – Free Report) from a strong-buy rating to a hold rating in a research report sent to investors on Monday morning,Zacks.com reports.
Several other research analysts also recently issued reports on XOS. Wedbush reduced their price target on shares of XOS from $15.00 to $12.00 and set an “outperform” rating on the stock in a research report on Thursday, August 15th. DA Davidson cut XOS from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $17.00 to $9.00 in a research note on Friday, August 16th. Roth Mkm started coverage on shares of XOS in a research note on Wednesday, October 23rd. They issued a “buy” rating and a $15.00 target price for the company. Northland Securities reaffirmed a “market perform” rating and set a $5.00 price target (down previously from $9.00) on shares of XOS in a research report on Monday. Finally, Roth Capital raised shares of XOS to a “strong-buy” rating in a research report on Wednesday, October 23rd. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, XOS has a consensus rating of “Moderate Buy” and an average price target of $10.25.
XOS Stock Down 4.8 %
XOS Company Profile
Xos, Inc designs, manufactures, and sells battery-electric commercial vehicles. The company provides class 5-6 medium duty rolling chassis, such as commercial stepvans and armored trucks; class 7-8 heavy duty chassis; and Xos product development. It offers Xos provides mix-use powertrain solutions for off-highway, industrial and other commercial equipment, and specialty vehicles, such as school buses, medical and dental clinics, blood donation vehicles, and mobile command vehicles.
Featured Articles
- Five stocks we like better than XOS
- How to Invest in Biotech Stocks
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Dividend Payout Ratio Calculator
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Retail Stocks Investing, Explained
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for XOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOS and related companies with MarketBeat.com's FREE daily email newsletter.